Rezolute Completes Phase 3 Enrollment for ersodetug
Rezolute (RZLT) completed Phase 3 enrollment for ersodetug in tumor hyperinsulinism, with topline results expected in mid-December 2026. Interim data showed 7 of 8 participants met the primary endpoint. Analysts have a $12.00 price target and a Buy rating, while AI analyst Spark rates it Neutral due to financial performance and regulatory signals.
How this was made
The 30-second read
Why it matters
The enrollment completion and positive interim results reduce clinical risk and may accelerate path to FDA filing, supporting a price rally.
Market read
New trial milestone for a micro‑cap biotech, likely to move the stock ahead of the Phase 3 readout.
What to watch
Potential regulatory delays or manufacturing scale‑up challenges could temper upside.
Background
Rezolute is a late‑stage biopharma focused on ultra‑rare hyperinsulinism disorders. The upLIFT study targets tumor‑induced hypoglycemia.
Ticker impact
Rezolute announced completion of enrollment in its Phase 3 upLIFT study of ersodetug, with interim data showing 7 of 8 participants met the primary endpoint.
likely upward pressure as investors price in favorable trial progress
Phase 3 enrollment completion and strong interim results are material new information for a biotech, often driving share price higher ahead of final data.
Market effects
May boost sentiment for rare‑disease biotech peers awaiting trial data.
Limited to US biotech sector.
Modest; primarily affects investors in biotech and rare‑disease space.
Counterpoint
If the Phase 3 data disappoint, the stock could face sharp downside.
Key entities
- companyRezolute, Inc.
US‑listed biotech developing ersodetug for hyperinsulinism.
